[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ibs---irritable-bowel-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ibs---irritable-bowel-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,76,99,125,148,170,190,213,238,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100634720","personalized-therapy-of-long-term-low-fodmap-in-ibs-treatment-role-of-mobile-application-and-microbiota-gut-brain-axis-100634720",false,"NCT07543354","Personalized Therapy of Long-term Low FODMAP in IBS Treatment: Role of Mobile Application and \"Microbiota-gut-brain\" Axis","Inclusion Criteria:\n\n* Participants aged between 20 and 65 years.\n* Diagnosed with Irritable Bowel Syndrome (IBS)\n* Overall IBS symptoms remain unresolved or active at the time of enrollment.\n\nExclusion Criteria:\n\n* Inability to understand the study procedures or provide written informed consent.\n* Currently pregnant.\n* History of Inflammatory Bowel Disease (IBD).\n* Active infection within the past 90 days.\n* History of thyroid disease.\n* Major psychiatric disorders, including patients with significant anxiety or depression currently requiring treatment with anti-anxiety or anti-depressant medications.\n* History of epilepsy.\n* History of stroke, cerebral hemorrhage, or other central nervous system diseases.\n* Significant renal, hepatic, or major cardiovascular diseases.\n* Malignant diseases (cancer).\n* Type 2 diabetes.\n* Other chronic pain conditions.\n* History of abdominal surgery (excluding cholecystectomy or appendectomy) or any history of brain surgery.\n* Appendectomy or cholecystectomy performed within the past year.\n* Currently participating in other clinical trials.\n* Use of antibiotics or analgesics within 90 days prior to enrollment.\n* Newly initiated use of probiotics or prebiotics within 90 days prior to enrollment.\n* Current use of antipsychotic medications, antidiarrheal agents, probiotics, or analgesics.","ALL","20 Years","65 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate the effectiveness of a mobile application (app) in helping clinicians and dietitians provide personalized low-FODMAP diet (LFD) therapy for patients with Irritable Bowel Syndrome (IBS). The study also aims to explore the potential biological mechanisms behind the clinical outcomes of this dietary intervention.\n\nParticipants diagnosed with IBS will be recruited and screened through clinical questionnaires. Eligible participants will receive dietary education from a dietitian and be randomly assigned to one of two groups: the AI-assisted LFDapp group or the LFD booklet group.\n\nThe study consists of three main phases:\n\nInitial Intervention (4-6 weeks): Participants will follow their assigned diet intervention and complete assessments regarding gastrointestinal symptoms, psychological traits (such as anxiety and depression), and quality of life.\n\nReintroduction Phase (12 weeks): Participants who respond well to the diet will enter a phase where specific foods are gradually reintroduced.\n\nPersonalization \\& Follow-up (4 weeks): A personalized diet will be established, followed by a final evaluation of bowel function and mental well-being.\n\nResearchers will use various standardized questionnaire to track changes in symptoms and overall well-being throughout the study period.",[26],"IBS - Irritable Bowel Syndrome",[28,29,30],"Low FODMAP","microbiota-gut-brain axis","IBS","NOT_YET_RECRUITING","2026-05-12",{"date":34,"type":35},"2026-05-15","ACTUAL",{"date":37,"type":20},"2026-04",{"date":39,"type":20},"2029-06",{"name":41,"class":42},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100616745","sucrase-isomaltase-si-genes-and-meal-load-100616745","NCT07309601","Sucrase-Isomaltase (SI) Genes and Meal Load","Comparison of a Meal Load Between Normal and Functional Variants of the Sucrase-isomaltase (SI) Gene in IBS","SI IBS","Inclusion Criteria:\n\n* Diagnosis of irritable bowel syndrome (IBS)\n* Gene testing has been conducted regarding genes regulating the production of sucrase-isomaltase ensymes in previous dietary interventions using the starch- and sucrose reduced diet (SSRD) or multi-center study.\n\nExclusion Criteria:\n\n* Diagnosis of inflammatory bowel disease, celiac disease, bile salt malabsorption, gastroenteritis or enteric dysmotility\n* Severe food allergy\n* Serious heart-, lung-, cardiovascular-, malignant- or mental illness\n* Ongoing eating disorder\n* Pregnancy\n* Recent major gastrointestinal surgery\n* Alcohol and\u002For drug addiction","18 Years","70 Years",{"count":55,"type":20},70,[23],"The goal of this interventional study is to examine whether those patients with irritable bowel syndrome (IBS) and a reduced abitility do degrade starch and sugar (lowe levels of enzymes) have lower raise in blood glucose after a meal than those with normal expression of enzymes. We also want to examine whether those IBS patients with reduced enzyme levels have increased bowel symptom in relation to this meal.\n\nThe main questions it aims to answer are:\n\nDoes reduced ability to degrade starch and sugar due to less enzyme activity lead to lower increase in blood glucose after a meal? Does reduced ability to degrade starch and sugar due to less enzyme activity lead to increased bowel symptoms after a meal?",[26,59],"Sucrase-Isomaltase Deficiency",[30,61,62,63,64],"SI genes","Starch and sucrose","blood glucose levels","bowel symptoms","RECRUITING","2026-04-28",{"date":68,"type":35},"2026-04-29",{"date":70,"type":35},"2026-02-01",{"date":72,"type":20},"2030-02-01",{"name":74,"class":75},"Region Skane","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100632695","gut-microbiome-in-patients-with-post-infectious-irritable-bowel-syndrome-100632695","NCT07517029","Gut Microbiome in Patients With Post-infectious Irritable Bowel Syndrome","Informed Ecological Rewiring of Gut Microbiome for Dysbiosis-associated Disorders","MicroRestore","PI-IBS patients (n = 105)\n\n* Inclusion criteria\n\n  * Age ≥ 18 years old\n  * PI-IBS diagnosed according to Rome IV criteria (33).\n  * Diagnosis no earlier than 3 months before enrollment.\n  * Written informed consent and compliance with study procedures.\n* Exclusion criteria\n\n  * Chronic organic gastrointestinal (GI) disorders (e.g. Inflammatory Bowel Disease -IBD), metabolic syndrome, obesity, diabetes, GI cancers, systemic autoimmune disorders.\n  * History of major abdominal surgery.\n\nControl cohort #1 - Post-infectious non-IBS (n = 105)\n\n* Inclusion criteria\n\n  * Age ≥ 18 years old\n  * History of acute infectious gastroenteritis \\>6 months before enrollment.\n  * Complete recovery without persistent GI symptoms.\n* Exclusion criteria\n\n  * Current or past diagnosis of IBS.\n  * Any chronic GI or systemic disorders.\n\nControl cohort #2 - Healthy subjects (n = 105)\n\n* Inclusion criteria\n\n  * Age ≥ 18 years old\n  * Healthy donors from FMT program or blood donor program.\n  * No history of GI or systemic disorders.\n* Exclusion criteria\n\n  * Any GI or systemic chronic condition.\n  * Recent antibiotics\u002Fprobiotics (\\\u003C4 weeks).\n  * Chronic medication affecting microbiome composition (e.g. PPI)",true,{"count":86,"type":20},315,"OBSERVATIONAL","Observational, multicenter, prospective study aimed at characterizing the gut microbiome in patients with post-infectious irritable bowel syndrome (PI-IBS) using whole genome sequencing (WGS). The study will compare microbiome composition and function between PI-IBS patients and two control groups (post-infectious subjects without irritable bowel syndrome -IBS- and healthy controls), with the goal of identifying reproducible microbial signatures and target taxa associated with disease and symptom severity.",[26,90],"Post Infection Syndrome","2026-04-08",{"date":93,"type":35},"2026-04-13",{"date":91,"type":35},{"date":96,"type":20},"2028-12",{"name":98,"class":75},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":17,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100501926","phase-3-ebastine-versus-mebeverine-in-ibs-patients-100501926","NCT05815602","Ebastine Versus Mebeverine in IBS Patients","Multicenter Randomized Controlled Clinical Trial Comparing Ebastine and Mebeverine as Treatment of Irritable Bowel Syndrome","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Patients fulfilling the Rome IV criteria for non-constipated IBS (IBS-C subtypes will be excluded)\n3. No organic cause that can explain the presenting symptoms (exclusion of coeliac disease (blood), lactose intolerance (breath test), inflammatory bowel disease and giardiasis (stool)\n4. Patients with lactose intolerance can be included if no improvement on lactose free diet during 6 weeks\n5. Age 18-65\n\nExclusion Criteria:\n\n1. History of coeliac disease, food allergy, giardiasis, inflammatory bowel disease, infectious gastroenteritis, motility disorder, serious liver kidney cardiac or pulmonary disease, known cardiac rhythm disorders, insuline-dependent diabetes, psychiatric diseases\n2. Pregnancy, breast feeding\n3. Medication: the use of antidepressants or antipsychotics, anti-allergic medication or drugs affecting gastrointestinal motility \u002F visceral sensitivity (anti-cholinergics, antispasmodics, 5-HT3 antagonists, 5-HT4 agonists, loperamide, codeine, laxatives, analgesics: only paracetamol is allowed as analgetic, other analgesics are forbidden.), CYP3A4-inducing and inhibiting drugs. Potent inhibitors of CYP3A4 include clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal and grapefruit. Inducers of CYP3A4 include phenobarbital, phenytoin, rifampicin, St. John's Wort and glucocorticoids.\n4. Symptoms started following abdominal surgery\n5. IBS constipation dominant (IBS-C)\n6. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the SmPC of the respective medicinal products",{"count":19,"type":20},[108],"PHASE3","Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome\n\nTrial rationale\n\n1. To perform a randomized superiority trial comparing the clinical efficacy of ebastine and mebeverine\n2. To evaluate the impact of treatment with ebastine compared to mebeverine on quality of life and quality-adjusted life years\n\nPrimary objective To provide further evidence of the superiority of histamine 1 receptor antagonism as novel treatment for patients with non-constipated IBS, as compared to mebeverine, one of the spasmolytics currently used as first line treatment of IBS.\n\nSecondary objective(s) To provide evidence that the histamine 1 receptor antagonist ebastine is more effective in reducing abdominal pain compared to the commonly used antispasmodic mebeverine",[26,30],[112,113,30,114],"ebastine","duspatalin","Irritable Bowel Syndrome","2026-03-19",{"date":117,"type":35},"2026-03-23",{"date":119,"type":35},"2023-03-30",{"date":121,"type":20},"2028-01-01",{"name":123,"class":75},"Guy Boeckxstaens",5,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":43},"100574534","early-phase-1-psilocybin-assisted-psychotherapy-in-treating-irritable-bowel-syndrome-ibs-100574534","NCT06760533","Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)","Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.","Inclusion Criteria:\n\n* Severe IBS patients meeting Rome IV criteria. Severe IBS is defined by IBS-SS \\>300, or one or more emergency room (ER) visit for abdominal pain in the last year.\n* Experiencing persistent IBS symptoms despite pharmacologic therapy\n* Have an identified support person\n* Agree to be accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing\n* Participants of childbearing potential must agree to practice an effective means of birth control throughout the duration of the study.\n* Participants must agree to send outside medical records in order for the study team to verify eligibility.\n\nExclusion Criteria:\n\n* Unstable medical conditions or serious abnormalities on complete blood count, chemistries, or ECG that in the opinion of the study physician would preclude safe participation in the trial. Some examples include:\n\n  * Congestive heart failure\n  * Clinically significant arrhythmias (e.g.,\n  * Ventricular fibrillation, torsades) or clinically significant ECG abnormality (i.e., corrected QT interval \\> 450)\n  * Recent acute myocardial infarction or\n  * Evidence of ischemia (in the last year)\n  * Malignant hypertension\n  * Congenital long QT syndrome\n  * History of valvular heart disease\n  * Acute renal failure\n  * Moderate to Severe hepatic impairment (Child Pugh class B and C).\n  * Respiratory failure\n  * Recent stroke (\\\u003C 1 year from signing of consent)\n  * Laboratory tests abnormalities (ALT ≥ 2X upper limit of normal (ULN), aspartate aminotransferase (AST) ≥ 2X ULN, Hemoglobin\\\u003C11.5, platelets \\\u003C150, White Blood Cells (WBC)\\>10, Sodium\\>150, Potassium K\\\u003C3.5 or K\\>5.2)\n  * Abnormal and clinically significant results on the physical examination (BP\\>139\u002F89 mmHG), heart rate (HR)\\>90bpm,\n  * History of Pulmonary hypertension\n* Significant central nervous system (CNS) pathology. Examples include:\n\n  * Primary or secondary cerebral neoplasm\n  * Epilepsy\n  * History of stroke\n  * Cerebral aneurysm\n  * Dementia\n  * Delirium\n* Primary psychotic or affective psychotic disorders. Examples include current or past DSM-5 criteria for:\n\n  * Schizophrenia spectrum disorders\n  * Schizoaffective disorder\n  * Bipolar I or II disorder with psychotic features\n  * Major Depressive Disorder\n  * Substance induced psychotic disorders\n  * Paranoid personality disorder\n  * Delusional disorder\n  * Borderline personality disorder\n  * Any other psychotic illness\n* Family history of psychotic or serious bipolar spectrum illnesses. Examples include first-degree relative with:\n\n  * Schizophrenia spectrum disorders\n  * Schizoaffective disorder\n  * Bipolar I disorder with psychotic features\n  * Any other psychotic illness\n* High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation. Examples include:\n\n  * Agitation\n  * Violent behavior\n* Active substance use disorders (SUDs) defined as Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine) within the past year\n* Clinically significant suicidality or high risk of completed suicide defined as:\n\n  * 'Yes' to C-SSRS Suicidal Ideation items 4 or 5 within the last 2 months at Screening or 'since last visit' at Baseline\n  * Any C-SSRS Suicidal Behavior item within the past 12 months at Screening or 'since last visit' at Baseline, as defined by 'Yes' to any of the following on the C-SSRS: actual attempt, interrupted attempt, aborted attempt, or preparatory acts\n  * Have any suicidal ideation or thoughts, in the opinion of the study physician or PI, that presents a serious risk of suicidal or self-injurious behavior\n* History of hallucinogen persisting perception disorder (HPPD)\n* Pregnancy\u002Flactation\n* Cognitive impairment as defined by: Montreal Cognitive Assessment Test (MoCA) \\\u003C 23\n* Concurrent Medications\n\n  * Antidepressants\n  * Centrally-acting serotonergic agents (e.g., monoamine oxidase inhibitors (MAOIs))\n  * Antipsychotics (e.g., first and second generation)\n  * Mood stabilizers (e.g., lithium, valproic acid)\n  * Aldehyde dehydrogenase inhibitors (e.g., disulfiram)\n  * Significant inhibitors of UGT 1A0 or UGT 1A10\n  * Niacin\n* Subjects should not also be taking serotonin-acting dietary supplements (such as 5-hydroxy-tryptophan or St. John's wort)\n* Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), Methadone, Opiates (Morphine, Oxycodone), Phencyclidine (PCP)\n* Have a psychiatric condition judged to be incompatible with establishment of rapport with the study therapists or safe exposure to psilocybin\n* Have any psychological or physical symptom, medication or other relevant finding prior to randomization, based on the clinical judgment of the PI or relevant clinical study staff that would make a participant unsuitable for the study.\n* Have an allergy or intolerance to either psilocybin on Niacin\n* Be enrolled in another clinical trial assessing intervention(s) for anxiety, depression, and\u002For existential distress (e.g., pharmacologic or psychotherapeutic interventions)\n* Are unable to provide external medical records or refuse to provide external medical records.","75 Years",{"count":134,"type":20},10,[136],"EARLY_PHASE1","This study will serve as a pilot randomized controlled trial to assess the feasibility of Psilocybin-Assisted Psychotherapy (PAP) in Treating Irritable Bowel Syndrome (IBS). Patients with severe IBS will undergo 3 pre-psychotherapy sessions with two licensed and trained psychedelic therapists, then will be randomized to undergo a guided psychotherapy session with single 25 mg oral \"high\" dose of psilocybin or a single 100 mg dose of niacin (active placebo) and attend 4 post-therapy integration sessions.",[26],"2026-03-03",{"date":141,"type":35},"2026-03-05",{"date":143,"type":20},"2026-08",{"date":145,"type":20},"2026-12",{"name":147,"class":75},"NYU Langone Health",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":43},"100568687","early-phase-1-novel-pilot-study-to-treat-symptoms-of-ibs-with-diarrhea-using-combination-therapy-of-a-low-fodmap-diet-and-a-neuromodulator-100568687","NCT06684470","Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator","Inclusion Criteria:\n\n* Participants must meet all of the inclusion criteria to participate in this study:\n\n  * Adults (ages 18-70)\n  * Score of \\>175 on the IBS-SSS questionnaire\n  * Must meet Rome IV criteria for IBS-D\n  * If subject is of reproductive capability a negative urine pregnancy test must be available prior to entering the study\n  * Ability to understand study procedures and to comply with them for the entire length of the study\n\nExclusion Criteria:\n\n* All candidates meeting any of the below exclusion criteria at baseline will be excluded from study participation:\n\n  * Score of \\\u003C 175 on the IBS-SSS\n  * Prior diagnoses of: known celiac disease, small intestinal bacterial overgrowth, inflammatory bowel disease, or microscopic colitis\n  * Ongoing significant anxiety or depression\n  * A history of a known side effect to mirtazapine\n  * Prior treatment with a low FODMAP diet or mirtazapine without clinical benefit\n  * Active alcohol or drug abuse\n  * Inability to read or understand the consent form\n  * Any other medical or psychological reason that would prevent active participation in a research study\n  * Pregnant females",{"count":155,"type":20},20,[136],"The purpose of this research is to study the added benefit of treating IBS symptoms with a medication called mirtazapine in treating IBS symptoms when paired with a low-FODMAP diet compared to a low-FODMAP diet alone. FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. These are short-chain carbohydrates that can cause digestive distress in some people.\n\nYou have been asked to take part in this research because you have symptoms of diarrhea-predominant irritable bowel syndrome that may respond to treatment with a combination of a medication called mirtazapine and a low-FODMAP diet.",[26,159],"Diarrhea",[159,30,114],"2025-12-10",{"date":163,"type":35},"2025-12-18",{"date":165,"type":35},"2024-12-19",{"date":167,"type":20},"2026-12-19",{"name":169,"class":75},"Mayo Clinic",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":17,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":43},"100494712","evaluating-the-impact-of-including-virtual-dietary-education-within-an-electronic-irritable-bowel-syndrome-pathway-100494712","NCT05721742","Evaluating the Impact of Including Virtual Dietary Education Within an Electronic Irritable Bowel Syndrome Pathway","Inclusion Criteria:\n\n* Recurrent abdominal pain on average at least 1 day\u002F week in the last 3 months associated with two or more of the following criteria: related to defecation, or association with a change in frequency of stool or associated with a change in form (appearance) of stool\n* Willingness to change diet\n* Access to a device for accessing virtual dietary education\n\nExclusion Criteria:\n\n* New onset symptoms within past year in age 50 and above\n* Rectal bleeding\n* Inflammatory Bowel Disease\n* Unexplained recent weight loss\n* Gastrointestinal surgery with removal of gallbladder or segments of the bowel\n* Having an eating disorder",{"count":177,"type":20},76,[23],"Irritable bowel syndrome is a functional bowel disorder that affects many Canadians. The syndrome involves abdominal pain and change in frequency or form of bowel movements, and these symptoms can lead to a decreased quality of life for patients. Primary care physicians are dissatisfied with current referral processes, and patients may wait a long time to receive the correct diagnosis. Diet is known to exacerbate symptoms of IBS. In Canada, accessing dietary treatment for IBS is a challenge due to lack of resources. Some patients lack access to dietary interventions, and others are given advice that is not evidenced based. Use of eHealth technology, such as virtual education delivered by a dietician, may allow for more widespread access to dietary interventions for IBS. Virtual education can include one on one dietary education, online group-based education, and the use of apps. Currently, there is a gap in knowledge whether dietary intervention for IBS, delivered virtually by a dietician, is effective in treating IBS.",[26],"2025-07-08",{"date":183,"type":35},"2025-07-09",{"date":185,"type":35},"2023-05-16",{"date":187,"type":20},"2026-05",{"name":189,"class":75},"Nova Scotia Health Authority",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":15,"minAge":196,"maxAge":53,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":199,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":43},"100532304","phase-2-the-use-of-directed-probiotics-in-mecfs-myalgic-encephalomyelitischronic-fatigue-syndrome-100532304","NCT06211062","The Use of Directed Probiotics in ME\u002FCFS: Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome","Inclusion Criteria: eligible if all of the following apply:\n\n* Meets IOM ME\u002FCFS case definition criteria,\n* Co-morbid IBS: meets RomeIV criteria for alternating or diarrhea-predominant IBS as reported during screening (technically diagnosed by a physician),\n* Able to provide consent to study,\n* Patients of childbearing potential must practice effective contraception during the study and be willing to continue contraception for at least six months after the intervention,\n* agrees to participate in online surveys and follow-up visits.\n\nExclusion Criteria: ineligible if any of the following apply:\n\n* Probiotics in the past eight weeks,\n* Antibiotics in the past eight weeks,\n* Pregnancy or lactating women,\n* Medical conditions including short bowel syndrome, celiac disease, biliary disease, pancreatitis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), severe cardiovascular, neurological condition, or liver failure,\n* Gastrointestinal surgery within six months of study entry,\n* History of psychiatric disorder, alcohol or illicit drug abuse.","45 Years",{"count":198,"type":20},100,[200],"PHASE2","This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME\u002FCFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are:\n\n* how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammation and normalize the GI and systemic\u002Fbrain interface?\n* how well is it working on IBS severity? The study sample is 100 male and female participants aged 45 to 70 years with ME\u002FCFS (per the Canadian Consensus Criteria); one-half of the participants will have co-morbid IBS (per Rome IV criteria). Participants will receive an i3.1 or a placebo and be assessed at baseline, at eight weeks, and at 12 weeks (four weeks post-treatment completion).",[203,26],"ME\u002FCFS","2025-03-03",{"date":206,"type":35},"2025-03-04",{"date":208,"type":35},"2022-12-20",{"date":210,"type":20},"2026-02-24",{"name":212,"class":75},"Nova Southeastern University",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":84,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":219,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":221,"conditions":222,"keywords":226,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":43},"100532624","capsule-microbiota-sampling-in-ibsfunctional-gastrointestinal-disease-100532624","NCT06215222","Capsule Microbiota Sampling in IBS\u002FFunctional Gastrointestinal Disease","Inclusion Criteria:\n\n* Males or females 18 years of age or older and 70 years of age or younger at the time of the first Screening Visit.\n* American Society of Anesthesiologists (ASA) Physical Status Classification System 1 or 2 (1-A normal healthy patient or 2-A patient with mild systemic disease)\n* For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit. Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence).\n* Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form.\n* Positive for at least one clinical symptoms consistent with SIBO and or IBS and or a Rome Diagnosis of functional GI disorder (Rome IV criteria)\n\nExclusion Criteria:\n\n* History of any of the following:\n\n  * Prior gastric or esophageal surgery, including lap banding or bariatric surgery\n  * Bowel obstruction\n  * Gastric outlet obstruction\n  * Diverticulitis\n  * Inflammatory bowel disease\n  * Ileostomy or colostomy\n  * Gastric or esophageal cancer\n  * Achalasia\n  * Esophageal diverticulum\n* Active Dysphagia or Odynophagia\n* Active medication use for any gastrointestinal conditions\n* Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding\n* Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study",{"count":220,"type":20},40,"We will sample intestinal microbiota using a microbiome sampling capsule in Healthy, Irritable Bowel Syndrome (IBS), and Functional Gastrointestinal Disease.",[26,223,224,225],"Healthy","Functional Bloating","Functional Gastrointestinal Disorders",[227,228],"microbiome","Small intestine","2024-01-10",{"date":231,"type":35},"2024-01-22",{"date":233,"type":35},"2023-11-16",{"date":235,"type":20},"2026-12-01",{"name":237,"class":75},"Stanford University",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":84,"sex":15,"minAge":52,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":4},"100521228","microbiome-sampling-in-gi-disease-with-a-focus-on-small-intestinal-microbial-assessment-100521228","NCT06066866","Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment","Inclusion Criteria:\n\n* Age \\>18years\n* Patients seen at Stanford University Digestive Health Center who are scheduled for an upper endoscopy as part of their Standard Of Care\n\nExclusion Criteria:\n\nChildren (under age 18years) Pregnant Women and Fetuses Neonates (0 - 28 days) Impaired Decision Making Capacity","100 Years",{"count":246,"type":20},150,"GI disorders are influenced by the gut microbiome. To date, sampling of the small intestine in GI disorders has been limited. The investigators plan to sample the small intestinal contents during endoscopy for research purposes.",[223,26,249],"Inflammatory Bowel Diseases","2023-10-04",{"date":252,"type":35},"2023-10-06",{"date":254,"type":20},"2024-01-01",{"date":121,"type":20},{"name":237,"class":75},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":43},"100379219","phase-3-ethosuximide-and-pentoxifylline-in-the-treatment-of-abdominal-pain-related-to-irritable-bowel-syndrome-100379219","NCT04217733","Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome","A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome","Inclusion Criteria:\n\n* • Age ≥ 18 years,\n\n  * Man and Women, Negative pregnancy test and effective contraception,\n  * IBS defined by the Rome criteria IV\n  * During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.\n  * IBS Treatment stable for 1 month\n\nExclusion Criteria:\n\n* • Breastfeeding\n\n  * Diabetic patients\n  * Significant liver function abnormalities (transaminases\\> 3N, cholestasis) and moderate renal disease (MDRD \\\u003C60 ml \u002F min)\n  * Addiction to alcohol and \u002F or drugs,\n  * Antiepileptic drugs taken (epilepsy or chronic pain)\n  * Chronic pain of greater intensity than that related to IBS,\n  * Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline.\n  * History or current severe depression (hospitalization, long-term antidepressant treatment)\n  * Psychotic disorders,",{"count":265,"type":20},60,[108],"Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome",[26],"2020-01-02",{"date":271,"type":35},"2020-01-03",{"date":273,"type":35},"2019-11-01",{"date":275,"type":20},"2030-12-30",{"name":277,"class":75},"Tanta University"]